1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Ernest Nadal(Institut Català d'Oncologia), T.M. Kim(Seoul National University), Valentina Guarneri(Istituto Oncologico Veneto), P.J. Voon(Sarawak General Hospital), Boon Khaw Lim(Sunway University), Marie Wislez(Assistance Publique – Hôpitaux de Paris), Cheng Huang(Fujian Provincial Cancer Hospital), Chong Kin Liam(University of Malaya), Julien Mazières(Université Toulouse III - Paul Sabatier), Lye Mun Tho(Hospital Kuala Lumpur), Hidetoshi Hayashi(Kindai University), N. Nguyen(Hanoi Lung Hospital), Puey Ling Chia(Tan Tock Seng Hospital), Filippo de Marinis(European Institute of Oncology), Sabine Brutlach(Merck (Germany)), Svenja Adrian(Merck (Germany)), Barbara Ellers‐Lenz(Merck (Germany)), Karin Berghoff(Merck (Germany)), Niki Karachaliou(Merck (Germany)), Yi‐Long Wu(Guangdong Academy of Medical Sciences)
Cited by 2Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis